Holds one valid CEP for mesalazine, filing since 2015. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 2 markets.
Holds 4 valid CEPs for mesalazine, filing since 2010. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 19 markets.
Holds 2 valid CEPs for mesalazine, filing since 2009. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 25 markets.
Holds one valid CEP for mesalazine, filing since 2024. Its 2024 FDA inspection closed as VAI, and its GMP is recognised in 4 markets.
Holds one valid CEP for mesalazine, filing since 2021. Its 2026 FDA inspection closed as VAI, and its GMP is recognised in 1 market.
Holds one valid CEP for mesalazine, filing since 2023. Its 2019 FDA inspection closed as VAI, and its GMP is recognised in 1 market.
Holds one valid CEP for mesalazine, filing since 2017. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 1 market.
Its GMP is recognised in 21 markets.
Its 2024 FDA inspection closed as VAI, and its GMP is recognised in 3 markets.
Its 2025 FDA inspection closed as VAI.
Holds one valid CEP for mesalazine, filing since 2021. Its 2022 FDA inspection closed as VAI, and its GMP is recognised in 1 market.
Its 2025 FDA inspection closed as VAI.
Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 1 market.
The names are listed below. The filings, inspection history and GMP certificates behind each one are available with a free account.
This page filters the worldwide Mesalazine manufacturer list to companies based in India. The order is set by active filings weighted by regulator, inspection outcomes and their recency, breadth of GMP recognition, and evidence of real exports, less any open risk flags. Read the full method.
Tell us which markets you need to file in. These suppliers come back tiered for those markets, with the price corridor and an RFI sheet.
Start for free